EMA Authorised: Paxneury (guanfacine hydrochloride) — Neuraxpharm Pharmaceuticals S.L.

View source ↗

Summary

The EMA has authorised Paxneury (guanfacine hydrochloride) for attention deficit disorder with hyperactivity, with Neuraxpharm Pharmaceuticals S.L. as the MAH.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• Paxneury (guanfacine hydrochloride)

Snippet

Status: Authorised. Therapeutic area: Attention Deficit Disorder with Hyperactivity. MAH: Neuraxpharm Pharmaceuticals S.L.. Decision date: 14/07/2026